SynthesisRespiratory research2010
The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.
Synthesis in Respiratory research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Long-acting beta2-agonists for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2013Pooled it
- Safety of indacaterol in the treatment of patients with COPD.International journal of chronic obstructive pulmonary disease · 2011Pooled it
- Article
- Respiratory parameters predict poor outcome in COPD patients, category GOLD 2017 B.International journal of chronic obstructive pulmonary disease · 2018Article
- Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis.Caspian journal of internal medicine · 2016Review
- Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2015Review
- A-kinase anchoring proteins: cAMP compartmentalization in neurodegenerative and obstructive pulmonary diseases.British journal of pharmacology · 2014Review
- Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.International journal of chronic obstructive pulmonary disease · 2014Review
- Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.Respiratory research · 2013Article
- Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Lung India : official organ of Indian Chest Society · 2013Article
- The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2013Review
- Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.Drugs · 2012Review
- β(2) -adrenoceptor agonists: current and future direction.British journal of pharmacology · 2011Review
- Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.Pulmonary medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is the 4th leading cause of mortality worldwide. Long-acting bronchodilators are considered first line therapies for patients with COPD but their effects on mortality are not well known. We performed a comprehensive systematic review and meta-analysis to evaluate the effects of long-acting bronchodilators on total mortality in stable COPD.
methodsUsing MEDLINE, EMBASE and Cochrane Systematic Review databases, we identified high quality randomized controlled trials of tiotropium, formoterol, salmeterol, formoterol/budesonide or salmeterol/fluticasone in COPD that had a follow-up of 6 months or longer and reported on total mortality. Two reviewers independently abstracted data from the original trials and disagreements were resolved by iteration and consensus.
resultsTwenty-seven trials that included 30,495 patients were included in the review. Relative risk (RR) for total mortality was calculated for each of the study and pooled together using a random-effects model. The combination of inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) therapy was associated with reduced total mortality compared with placebo (RR, 0.80; p = 0.005). Neither tiotropium (RR, 1.08; p = 0.61) nor LABA by itself (RR, 0.90; p = 0.21) was associated with mortality.
conclusionsA combination of ICS and LABA reduced mortality by approximately 20%. Neither tiotropium nor LABA by itself modifies all-cause mortality in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.